|
Achembach
T. Manual for the Child Behaviour CheckList/ 4-18 and 1991 profile.
Burligton, University of Vermont, 1991.
American
Academy Child & Adolescent Psychiatry. Practice parameters for the
assessment and treatment of Attention Deficit Hyperactivity Disorder. J
Am Acad Child Adolescent Psychiatry 1997; 36: 85S-121S.
American
Academy Child & Adolescent Psychiatry. Practice parameters for the
use of stimulant medication in children, adolescent and adults. J
Am Acad Child Adolescent Psychiatry 2002; 41: 26S-49S
American
Academy of Pediatrics. Clinical Practice Guideline: Treatment of
school-aged child with Attention
Deficit Hyperactivity Disorder. Pediatrics 2001; 108:
1033-1044.
American
Academy of Pediatrics. Diagnostic evaluation of the child with Attention
Deficit Hyperactivity Disorder. Pediatrics 2000; 105:
1158-1170.
American
Psychiatric Association, Diagnostic and Statistical Manual of
mental Disorders, 4th ed (DSM-IV). Washington, DC: American
Psychiatric Association. 1994.
Andersen
SA, Arvanitogiannis A, Pliakas AM, LeBlanc C, Carlezon Jr. WA. Altered
responsiveness to cocaine in rats exposed to methylphenidate during
development. Nature Neuroscience 2002; 5:13-14.
Arnsten
AF. Genetics of childhood disorders: XVIII. ADHD, Part. 2:
Norepinephrine has a critical modulatory influence on prefrontal
cortical function. J Am Acad Child Adolesc Psychiatry
2000;39:1201-3.
Arnsten
AF, Steere JC, Hunt RD. The contribution of alpha 2-noradrenergic
mechanisms of prefrontal cortical cognitive function. Potential
significance for attention-deficit hyperactivity disorder. Arch Gen
Psychiatry 1996;53:
448-55.
Barkley
RA Handbook of attention deficit disorder 2nd ed.
New York Guilford 1998
Barkley
R.A. Behavioral inhibition, sustained attention, and executive
functions: constructing a unifying theory of ADHD. Psychol Bull.
1997; 121: 65-94.
Barkley
RA, Guevremont DC, Anastopoulos AD.
et al. A comparison of three family therapy programs for
treating family conflicts in adolescents with ADHD. J.
Consult. Clin. Psychol. 1992; 3: 450-462.
Barkley
R.A., McMurray M.B., Edelbroch C.S., Robbins K. Side effects of
methylphenidate in children with ADHD: systemic, placebo-controlled
evaluation. Pediatrics 1990;
86: 184-192.
Barr
CL. Genetics of childhood disoders: XXII.adhd, part 6: the dopamine D4
receptor gene J Am Acad Child Adolescent Psychiatry 2001; 40:
118-121.
Battaglia
G, Yeh SY, O'Hearn E, Molliver ME, Kuhar MJ, De Souza EB.. 3,4-Methylenedioxymethamphetamine
and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat
brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled
serotonin uptake sites. J Pharmacol Exp Ther. 1987; 242:
911-916.
Bradley
C. The behaviour of children receiving benzedrine. Am. J.
Psychiatry 1937; 94: 577-585.
Biederman
J., Wilens T.,, Mick E., Spencer T, Faraone SV. Pharmacotherapy of
attention defict-hyperactivity disorder reduce risk for substance use
disorder . Pediatrics 1999; 104: e20*.
Biederman
J. Spencer TJ. Genetics of childhood disorders: XIX. ADHD, Part. 2: is
ADHD a noradrenergic disorder? J Am Acad Child Adolesc Psychiatry
2000;39: 1330-1333.
Bloom
DR, Levin HS, Ewing-Cobbs L; Lifetime and novel psychiatric disorders
after pediatric traumatic brain injury.J. Am. Acad Child Adolesc.
Psychiatry 2001; 40:
572-579.
Buitelaar
J, Van deer Gaag RJ, Swaab-Barneveld H, Kuiper M. Prediction of
clinical response of methylphenidate children with in
Attention Deficit-Hyperactivity Disorder J. Am. Acad Child Adolesc.
Psychiatry 1995; 34: 1025-1032.
Bush
G, Frazier JA, Rauch SL, Seidman LJ, Whalen PJ, Jenike MA, Rosen BR,
Biederman J. Anterior cingulate cortex dysfunction in attention
deficit /hyperactivity disorder revealed by fMRI and counting Stroop. Biol.
Psychiatry 1999; 45: 1542-1552.
Camerini
G, Coccia M, caffo E. Il Disturbo da Deficit dell’Attenzione-Iperattività:
analisi della frequenza in una popolazione scolastica attraverso
questionari agli insegnanti. Psichiatria dell’infanzia e
dell’adolescenza, 1996; 63: 587-594
Cantwell
D.P. Attention deficit disorder: a review of the past 10 years. J
Am Acad Child Adolesc Psychiatry 1996; 35, 978-987.
Casey
B.J., Castellanos F.X., Giedd J.N., et al. Implication
of right frontostriatal circuitry in response inhibition and attention
-deficit hyperactivity disorder. J. Am Acad. Child Adolesc. Psychiatry
1997; 36: 374-383.
Castellanos
FX, Lau E, Tayebi N, et al. Quantitative
brain magnetic resonance imaging in attention-deficit hyperactivity
disorder. Arch. Gen. Psychiatry
1996; 53: 607-616.
Cianchetti
C, Sannio-Fancello G. Scale di Autosomministrazione per il
fanciullo e l’Adolescente (SAFA) Organizzazioni Speciali,
Firenze. 2001
Cook
E.H., Stein M.A., Krasowski M.D., et al. Association of attention
deficit disorder and the dopamine transporter gene. Am. J. Hum.
Genet. 1995; 56, 993-998.
Conners
CK. Conners’ rating scales- Revised. Technical manual
Multi-Health System, Toronto, Canada,1997
Conners
CK, Epstein JN, March JS, Angold A et al.
Multimodal treatlment of ADHD in the MTA: an alternative
analysis. .
J Am Acad Child Adolescent Psychiatry 2001; 40: 159-167.
Dunnick
JK, Hailey JR. Experimental studies on the long-term effects of
methylphenidate hydrochloride. Toxicology
1995; 103: 77-84
Doyle
AE, Biederman J, Seidman LJ, Weber W, Faraone SV. Diagnostic
efficiency of neuropsychological test scores for discriminating boys
with and without attention deficit-hyperactivity disorder. J
Consult Clin Psychol. 2000; 68: 477-488
DuPaul
GJ, Barkley RA, Anastopoulos AD,
Reid R. ADHD Rating scale -IV.Checklisti, norms and clinical
Interpretation. Guilford, New York 1998.
Elia
J, Ambrosini PJ, Rapoport JL. Treatment
of attention deficit hyperactivity disorder. New Engl.J.Med.
1999; 340: 780-788.
Faraone
SV, Doyle AE, Mick E, Biederman J. Meta-Analysis of the Association
Between the 7-Repeat Allele of the Dopamine D4 Receptor Gene and
Attention Deficit Hyperactivity Disorder . Am. J. Psychiatry
2001; 158:1052–1057.
Filipek
PA, Semrud-Clikeman M, Steingard RJ et al.. Volumetric MRI analysis
comparing subjects having attention-deficit hyperactivity disorder
with normal controls. Neurology 1997; 48: 589-601.
Fisher
SE, Francks C, McCracken JT. Et
al, A Genomewide Scan for Loci Involved in Attention-Hyperactivity
Disorder Am. J. Hum. Genet. 2002; 70:1183–1196.
Firestone
P. Kelly MJ, Goodman JT et al. Differential effects of parent training
and stimulant medicationwith hyperactives. J. Am. Acad Child
Adolesc. Psychiatry 1981;
20: 135-147.
Firestone
P. Crowe D, Goodman JT Vicissitudes of follow-up studies: differential
effects of parent training and stimulant medication with hyperactives.
Am.J.
Ortopsychiatry
1986; 56: 185-194.
Frowein,
HW. Selective effects of barbiturate and amphetamine on information
processing and response execution. Acta Psychologica. 1981; 47:
105-115.
Gadow
KD., Nohal EE., Sverd J., Sprakkin J, Paolicelli L. Methylphenidate in
aggressive-hyperactive boys: I. Effects on peer aggression in public
school settings. J Am Acad Child Adolesc Psychiatry 1990; 29,
710-715.
Gallucci
F, Bird HR, Berardi C, et al.. Symptoms
of Attention deficit hyperactivity disorder in an Italian school
sample: finding of a pilot study. J. Am. Acad. Child Adolesc.
Psychiatry 1993; 32,
1051-1058.
Gillberg
C., Melander H., von Knorring A-L. et al. Long-term stimulant
treatment of children with attention deficit hyperactivity symptoms. Arch
Gen Psychiatry 1997; 54, 857-864.
Goldman-Rakic
P.S. Dopamine mediated mechanism of prefrontal cortex. Semin
Neurosci. 1992; 4: 149-159.
Guevara JP, Stein MT. Evidence
based management of attention deficit hyperactivity disorder. Br
Medical Journal. 2001;323:1232-1235.
Highfield
DA, Hu D, Amsel A. Alleviation of x-irradiation-based deficit in
memory-based learning by D-amphetamine: Suggestions for attention
deficit– hyperactivity disorder. Proc. Natl. Acad. Sci. USA
1998; 95: 5785–5788
Hill
P, Taylor E. An auditable protocol for treating attention deficit/hyperactivity
disorder. Arch.
Dis. Child 2001;
84: 404-409.
Horn
WF, Ialongo N, Pascoe JM. Addictive effects of psychostimulants ,
parent training and self-control therapy with ADHD children: a 9
months follow-up. J. Am. Acad Child Adolesc. Psychiatry
1991; 32:
182-189.
Kovacs
M. Children Depression Inventory, Multi Health System, Toronto
, Canada, 1992.
LaHoste
GJ, Swanson JM, Wigal SB, et al. Dopamine D4 receptor gene
polymorphism is associated with attention deficit hyperactivity
disorder. Mol Psychiatry 1996; 1:121-124.
Hechtman
L. Assessment and diagnosisi of Attention-Deficit/Hyperactivity
Disorder. In:
Stubbe DE (ed.) Attention-Deficit/Hyperactivity
Disorder
. Child Adolesc. Clin. North America 2000; 9: 481-498.
Horrigan
JP, Barnhill LJ. Guanfacine and secondary mania in children. J
Affect Disord 1999;54:309-314
International
Consensus Statement on ADHD European Child & Adolescent
Psychiatry 2002; 11:
96-98.
Lonigan
CJ, Elbert JC, Johnson SB; Empirically supported psychosocial
interventions for children. J.Clin. Child Psychol. 1998; 27:
138-145.
Lou
HC, Andresen J, Steinberg B, McLauglin T, Friberg L. The striatum in a
putative cerebral network activated
by verbal
awareness in normal and ADHD children. Eur. J. Neurol.
1998; 5: 67-64.
Jaffe
SL. Failed attemps at intranasal abuse of Concerta. J Am Acad Child
Adolesc Psychiatry 2002; 41: 5.
Jensen
PS, Mrazek D, Knapp PK et al. Evolution and revolution in child
psychiatry: ADHD as a disorder of adaptation.
J Am Acad Child Adolesc Psychiatry 1997; 36: 1672-1679.
Jensen
PS . Attention-Deficit/Hyperactivity Disorder: concepts on etiology,
pathophysiology and neurobiology. In:
Stubbe DE (ed.) Attention-Deficit/Hyperactivity
Disorder
. Child Adolesc. Clin. North America 2000; 9: 557-572.
Joughin
C, Zwi M.FOCUS on the use of stimulants in children with
Attention-Deficit/Hyperactivity Disorder. Primary evidence-based
Briefing n.1. College research Unit. Royal College of Psychiatrist
London. 1999.
Kanotchvil
CJ, Bohac D, Harrington M, Baker N, May D, Burke WJ. An open label
trial with tomoxetine in pediatric attention deficit hyperactivity
disorder. J. Child Adolesc. Psychopharmacology 2001; 11:
167-170.
Kernberg
P F, Chazan SL, Normandin L, The Children’s Play Therapy Instrument
(CPTI) Journal of Psychotherapy Practice and Research, 1998; 7:
196-207
King
R A and The Work Group on Quality Issues, Practice Parameters for the
Psychiatric Assesment of Children and Adolescents. J.
Am. Acad. Child Adolesc. Psychiatry, 1995; 31:1386-1402./ J. Am. Acad.
Child Adolesc. Psychiatry, 1997; 36(10 Supplement):4S-20S (reprint)
Klorman
R., Brugmaghim JT., Fitzpatrick PA., Borgstedt AD. Methylphenidate
speeds evaluation processes of attention deficit disorder adolescents
during continuous performance test. J Abnorm Child Psychol
1991; 19: 263-283.
Komrad
K, Gauggel S, Manz A. Scholl M. Inhibtory control in children with
traumetic brain Injury (BTI) and children with attention defict/hyperactivity
disorder (ADHD). Brain
Inj.
2000; 14: 859-875.
Mahalick
DM, Carmel PW, Greenberg JP. Et al. Psychopharamcologic treatment of
acquired attention disorders in children with brain injury. Pedistr.
Neurosurg. 1998; 29: 121-126.
Mannuzza
S., Klein R.G., Bessler A., Malloy P, LaPadula M. Adult psychiatric
status of hyperactive boys grown up. Am. J. Psychiatry
1993; 155: 493-498.
Mannuzza
S., Klein R.G. Longterm prognosis of Attention-Deficit/Hyperactivity
Disorder. In:
Stubbe DE (ed.) Attention-Deficit/Hyperactivity
Disorder
. Child Adolesc. Clin. North America 2000; 9: 711-726.
March
J. Multidimensional anxiety Scale for Children, Multi Health
System Inc. Toronto,
Canada, 1997
Marzocchi
G. M., Di Pietro M., Bassi E., Filoramo G., Salmaso A. (inviato per la
pubblicazione). A
behavioral training for managing inattention, hyperactivity and
oppositional behaviors at school.
Marzocchi
GM, Oosterlaan J, DeMeo T, Di Pietro M, Pezzica S, Cavolina P,
Sergeant JA, Zuddas A. Scala di valutazione dei Comportamenti
Dirompenti per insegnanti (SCOD-I): validazione e standardizzazione di
un questionario per la valutazione dei comportamenti dirompenti a
scuola. Giorn. Neuropsichiatria Età Evol. 2001; 21, 378-393.
Marzocchi
G.M., Oosterlaan J., De Meo T., Di Pietro M., Pezzica S., Cavolina P.,
Sergeant J.A., Zuddas A. (inviato per la pubblicazione). Comportamenti
di disattenzione, iperattività e oppositività secondo i genitori: un
questionario per la valutazione dei comportamenti dirompenti (SCOD-G)
in età evolutiva.
Mataro
M, Garcia-Sancuez C, Junque C, Estevez-Gonzales A, Pujul J. Magnetic
resonance imaging measurement of the caudate nucleus in adolescents
with attention-deficit hyperactivity disorder and its relationship
with neuropsychological and behavioral measures. Arch. Neurol.
1997; 54: 963-968.
Mehta
MA, Owen AM, Sahakain BJ, et
al. Methylphenidate enhance working memory by modulating discrete
frontal and parietal lobe region in the human brain. J.Neuroscience
2000; 20: RC65 (1-6)*.
Michelson
D, Faries D, WernickeJ, Kelsey D,
Kendrick K, Sallee FR, Spencer T, Atomoxetine Study Group.
Atomoxetine treatment of children and adolescents with
attention-deficit hyperactivity disorder: a randomized,
placebo-controlled, dose-response study. Pediatrics 2001;
108: E83*
MTA
Cooperative Group A 14-month randomized clinical trial of treatment
strategies for attention-deficit/hyperactivity disorder. Archives
General Psychiatry 1999; 56: 1073-1086;
MTA
Cooperative Group. Moderators and mediators of treatment response for
children with attention-deficit/ hyperactivity disorder. Archives
General Psychiatry 1999; 56: 1088-1096.
Musten
LM, Firestone P, Pisterman S, Bennet S, Mercer J. Effects of
methylphenidate on preschool children with ADHD: cognitive and
behavioral functions. J Am Acad Child Adolesc Psychiatry 1997;
15: 1407-1415.
National
Institute for Clinical Excellence. Guidance on the use of
Methylphenidate (Ritalin, Equasym) for Attention Deficit Hyperactivity
Disorder. 2000 (www.nice.org.uk)
National
Institues of Health Consencus Development
Conference Statemet on “Diagnsi and treatment of Attention-Deficit/Hyperactivity
disorder 1998 http://odp.od.nih.gov/consensus/cons/110/110_statement.htm
O’Toole
K., Abramowitz A., Morris R, Dulcan M. Effects of methylphenidate on
attention and nonverbal learning in children with ADHD. J Am Acad
Child Adolesc Psychiatry 1993; 36: 531-538.
Pelham
W, Gnagy EM, Greenslade KE, Milich R. Teacher Ratings of DSM-III-R
Symptoms for the Disruptive Behaviour Disorders. Journal of
American Academy of Child and Adolescent Psychiatry 1992; 31: 210-218.
Pelham
WE Jr., Wheeler T, Chronis A. Empirically supported psychosocial
treatments for attention deficit hyperactivity disorder. J.Clin.
Child Psychol. 1998; 27: 190-205.
Pelham
WE Jr, Hoza B; Comprehensive treatment for ADHD: a proposal for
intensive summer treatment programs and outpatient follow-up. In:
Hibbs E, Jensen p (eds) Psychosocial treatment research of children
and adolescent disorders. Washington DC, America Psychiatric Press
1996, pp. 311-340
Pelham
WE Jr, Hinshaw S. Handobook of Clinical Behavioral Therapy, New
York, Wiley 1992
Pelham
W, Gnagy EM, Burrows-Maclean L et al. Once-a-day Concerta
methylfenidate versus three-times-dayly methylfenidate in laboratory
and natural setting. Pediatrics 2001 107: E 105 *
Pfiffner
LJ, McBurnett K, Social skill trainig with parent generalization:
treatment effects for children with ADD/ADHD. J.
Consult. Clin. Psychol. 1997;
65: 749-757.
Pisterman
S, Firestone P, Mc Grath P et al. Outcome of parent training in the
therapy of preschooler with ADHD. Am.J. Ortopsychiatry
1992; 62: 397-408.
Pliszka
SR, McCracken JT, Maas JW. Catecholamines in attention-deficit
hyperactivity disorder: current perspectives. J Am Acad Child
Adolesc Psychiatry. 1996;
35: 264-272.
Pochon
JB, Levy R, Fossati P , Lehericy S, et al. The neural system that
bridges reward and cognitionin humans: An fMRI study 2002; Proc. Natl.Acad.Sci.
USA 2002; 99: 5669–5674
Posner
M.I. and Peterson S.E. The attention system of the human brain. Ann
Rev Neurosci 1990; 13: 25-42.
Prince
JB, Wilens TE, Biederman J, Spencer TJ, Millstein R, Polisner DA,
Bostic JQ. A controlled study of nortriptyline in children and
adolescents with attention deficit hyperactivity disorder. J Child
Adolesc Psychopharmacol. 2000; 10: 193-204.
Quay
HC. Theories of ADDH. J Am Acad. Child Adolescent
Psychiatry 1988; 27: 262-263.
Quay
HC. Inhibition and attention deficit hyperactivity disorder. J
Child Psychol. Psychiatry
1997, 25:
7-13.
Rapoport
J.L. and Castellanos F.X. Attention deficit hyperactivity disorder. In
J.M. Weiner (Ed) Diagnosis and psychopharmacology of childhood and
adolescent disorders. 2th ed. New York: Wiles & Sons. 1996;
pp. 265-280.
Reich
W. Diagnostic Interview for Children and Adolescents (DICA). J Am
Acad. Child Adolescent Psychiatry
2000;39:59-66.
Richter
JE, Arnold LE Jensens et al. NIMH collaborative multisite,
multimodal treatment study of Children with ADHD; I. Background
and rationale. J Am Acad. Child Adolescent
Psychiatry 1995;
34: 987-1000.
Rubia
K, Taylor E, Smith AB, Oksannen H, Overmeyer S, Newman S.
Neuropsychological analyses of impulsiveness in childhood
hyperactivity. Br. J. Psychiatry 2001; 179: 138-143.
Sanders,
AF. Elements of human performance: Reaction processes and attention
in human skill. Lawrence Erlbaum. 1998; Mahwah, NJ.
Santosh
PJ, Taylor E. Stimulant Drugs . Eur. J. Child Adolesc. Psychiatry
2000; 9 (suppl.1) 27-43.
Schachar,
R., Logan, G. Are hyperactive children deficient in attentional
capacity? J. Abnormal Child Psychology 1990; 1: 493-513.
Schachar
R, Tannock R, Cunningham C, Corkum P; Behavioral, siyuational and
temporal effects of treatment of ADHD
with methylfenidate. J Am Acad Child Adolesc Psychiatry 1997;
36: 754-763.
Schachar
R, Taylor E., Wieselberg M., Thorley G. and Rutter M. Changes in
family function and relationships in children who respond to
methylphenidate. J Am Acad Child Adolesc Psychiatry
1987; 26: 728-732.
Scahill
L, Chappell PB, Kim YS, Schultz RT, Katsovich L, Shepherd E, Arnsten
AF, Cohen DJ, Leckman JF. A placebo-controlled study of guanfacine in
the treatment of children with tic disorders and attention deficit
hyperactivity disorder. Am J Psychiatry 2001;158:1067-1074
Scheres
A, Oosterlaan J, Sergeant JA. Response inhibition in children with AD/HD
and other disruptive disorders:the role of behhavioural activation. J
Chil Psychol. Psychiatry 2001; 42: 347-357.
Seeman
P, Madras BK. Mechanism of drug action. Anti-hyperactivity medication:
methylphenidate and amphetamine. Molecular Psychiatry 1998; 3:
386–396
Sergeant
JA, Oosterlaan J, Meere JJ. van der. Information processing and
energetic factors in attention-deficit/Hyperactivity disorder. In :
Quay HC, Hogan (eds) Handbook
of Disruptive Behavior Disorders, Plaenum press, NewYork, pp.
74-104. 1999.
Silberstain
RB, Farow M, Levy F et al.. Functional brain electrical activity
mapping in boys with attention deficit disorder Arc. Gen.
Psychiatry 1998; 55: 1105-1112.
Singer
HS, Brown J, Quaskey S, et,al,. The treatment of attention-deficit
hyperactivity disorder in Tourette's syndrome: a double-blind
placebo-controlled study with clonidine and desipramine. Pediatrics.
1995; 95: 74-81.
Smalley
SL, Bailey JN, Palmer CG, et al. Evidence that the dopamine D4
receptor is a susceptibility gene in attention deficit hyperactivity
disorder. Mol
Psychiatry 1998; 3:427-430.
Solanto
MV. Neuropharmacological
mechanisms of stimulant drug action in attention deficit/hyperactivity
disorder: a review and integration. Behavioral Brain Res. 198; 94:
127-152.
Sonuga-Barke
EJS, Williams E, Hall M, Saxton T. Hyperactivity and delay aversion.
III: the effects on cognitive style of imposing delay after errors. J
Child Psychol. Psychiatry 1996, 37, 189-194.
Sonuga-Barke
EJS, Dalay D, Thompson M. et al. Parent-based therapies for preschool
attention defict hyperactivity disorder: a randomized, controlled
trial with a community sample. J. Am. Acad Child Adolesc.
Psychiatry 2001; 40:
402-408.
Sonuga-Barke
EJS, Dalay D, Thompson M. Does maternalADHD reduce effectiveness of
parent trainig for preschool children’s ADHD? J. Am. Acad Child
Adolesc. Psychiatry
2002; 41:
696-702.
Spencer
T, Biederman J, Heiligenstein J et al. An open-label, dose ranging
study of atomoxetine in children with attention deficit hyperactivity
disorder. J. Child Adolesc. Psychopharmacology 2001; 11:
251-265.
Spencer
T, Biederman J, Wilens T, et al. Pharmacotherapy of attention deficit/hyperactivity
disorder accross the life-cycle. J Am Acad Child Adolescent
Psychiatry 1996; 35: 409+4032.
Spencer
T, Biederman J, Wilens T, et al. Effectiveness and tolerability of
tomoxetine in adults with attention deficit hyperactivity disorder. Am
J Psychiatry. 1998; 155: 693-695.
Still
GF. TheCoulston lecture on some abnormal physical condition in
children. Lancet 1902; 1: 1008-1012.
Stubbe
DE, Weiss G. Psychosocial interventions In: Stubbe DE (ed.) Attention-Deficit/Hyperactivity
Disorder Child Adolesc. Clin. North America 2000; 9: 663- 670.
Sunohara
GA, Roberts W, Malone M, Schachar RJ. Et al. Linkage of the Dopamine
D4 receptor gene and attention deficit disorder / hyperactivity
disorder. J Am Acad Child Adolescent Psychiatry1999; 39:
1537-1542.
Swanson
J.M., Sergeant J.A., Taylor E, et al,. Attention-deficit hyperactivity
disorder and hyperkinetic disorder. Lancet
1998; 351, 429-433.
Swanson
JM, Castellanos FX, Murias M, LaHoste G, Kennedy J. Cognitive
neuroscience of attention deficit hyperactivity disorder and
hyperkinetic disorder. Curr. Op. Neurobiology 1998; 8, 263-271.
Swanson
JM, Wigal S, Greenhill
LL. et al. Analog classroom assesment of Adderal in childrenwith ADHD.
J Am Acad Child Adolescent Psychiatry 1998; 37: 519-526.
Swanson
JM, Volkow N. Pharmacokinetic and pharmacodynamic properties of
stimulants: Implications for the design of new treatments for ADHD.
6th Internet World Congress for Biomedical Sciences www.uclm.es/inabis2000/symposia/files/126/index.htm
Tannock
R. Attention deficit hyperactivity disorder: advance in cognitive,
neurobiological, and genetic research. J Child Psychol Psychiatry 1998; 39: 65-99.
Task
Force on promotion and dissemination
of Psychological Procedures. Trainig in and dissemination of
empirically validated psychosocial treatment. Report and
reccomendation. Clin. Psychol. 1995; 48: 3-24.
Taylor
E, Physical treatment. In: Rutter M, Taylor E, Hersov L, eds, Child
and Adolescent Psychiatry, Blackwell Science, London, 1994.
Taylor
E, Chadwick O, Heptinstall E, Danckaerts M. Hyperactivity and conduct
problems as risk factors for adolescent development. J Am Acad
Child Adolescent Psychiatry 1996; 35:1213-1216.
Taylor
E, Sergeant J, Doepfner M, et al. Clinical guidelines for hyperkinetic
disorder. European society for child and adolescent
psychiatry. Eur Child Adolesc Psychiatry 1998; 7:
184-200.
Teicher
MH, Anderson CM, Polcari A, Glod CA, Maas LC, Renshaw PF. Funtional
defict in basal ganglia of childen with attention-defict/hyperactivity
disorder shown with funtional magnetic resonance imaging relaxometry. Nature Medicine 2000; 4: 470-473.
The
Tourette's Syndrome Study Group. Treatment of ADHD in children with
tics: a randomized controlled trial. Neurology 2002;58:527-36.
Thomas
GV, Silk AM, An introduction to the psychology of children’s
drawings. New York University Press. New York, 1990
Vaidya
CJ, Austin G, Kirkorian G, et al. Selective effects of methylphenidate
in attention deficit disorder: a functional magnetic resonance study. Proc.
Natl.Acad.Sci. USA. 1998; 95: 14494-14499.
Volkow
ND, Ding YS, Fowler JS, Wang GJ, et al. Is
methylphenidate like cocaine? Studies on their pharmacokinetics and
distribution in the human brain. Arch Gen Psychiatry. 1995;
52:456-63.
Volkow
ND Wang GJ, Fowler JS, et al. Dopamine transporter occupancies in the
Human Brain induced by therapeutic doses of oral methylphenidate. Am
J. Psychiatry 1998;
155: 1325-1331.
Volkow
ND, Wang G-J, Fowler JS, et al. Therapeutic
Doses of Oral Methylphenidate Significantly Increase Extracellular
Dopamine in the Human Brain. J.
Neurosci. 2001 : RC121*.
Waldman
ID, Rowe DC, Abramowitz A, et al. Association and linkage of the
dopamine transporter gene and attention-deficit hyperactivity disorder
in children: heterogeneity owing to diagnostic subtype and severity. Am
J.Hum Genet 1998; 63:1767-76.
Wilens
TE, Biederman J, Spencer T. et al.. A pilot controlled clinical trial
of ABT-418, a cholinergic agonist, in the treatment of adults with
attention deficit hyperactivity disorder. Am J Psychiatry.
1999;156:1931-1937.
Wilens
TE, Spencer TJ, Biederman J, et al. A Controlled Clinical Trial of
Bupropion for Attention Deficit Hyperactivity Disorder in Adults. Am J
Psychiatry. 2001; 158: 282-288.
Wolraich
ML, Greenhill LL, Pelham W et al. Randomized controlled trial of oros
methylphenidate once a day in children with for Attention Deficit
Hyperactivity Disorder. Pediatrics
2001; 108: 883-892.
World
Health Organization. The ICD-10 Classification of Mental and
Behavioral Disorders: Clinical Descriptions and Diagnostic Guidelines,
10th revision. Geneva:
World Health Organisation; 1992.
Yuan
J, McCann U, Ricaurte G. Methylphenidate and brain dopamine
neurotoxicity.. Brain Res. 1997; 767:172-5.
Zhuang
X., Oosting RS, Jones RS, et al. Hyperactivity and impaired response
habituation in hyperdopaminergic mice. Proc.Natl.Academy of Science
USA 2001; 98:1982-1987.
Zuddas
A, Ancilletta B, DeMuro S, Marongiu A, Cianchetti C. Protocollo
diagnostico, test di somministrazione acuta e terapia cronica con
metilfenidato in bambini con disturbo da deficit attentivo ed
iperattività: uno studio pilota. Psichiatria dell'Infanzia e
dell'Adolescenza 66: 735-746; 1999.
Zuddas
A. Ancilletta B, Muglia P, Cianchetti C. Attention-Deficit/Hyperactivity
Disorder: a neuropsychiatric disorder with childhood onset. Eur. J.
Paediatric Neurology 4:
53-62; 2000.
|
Torna alle Linee Guida